Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer To Market Alza Viadur In U.S.; Weighs International Agreement

Executive Summary

Bayer is considering an international marketing arrangement for Alza's Viadur following an agreement to market the long-acting leuprolide acetate implant for prostate cancer in the U.S.

You may also be interested in...

Alza Considering Viadur Marketing Partner For Late 2000 Launch

Alza is considering whether to find a marketing partner for Viadur in anticipation of a late 2000/early 2001 launch for the long-acting implant for palliative treatment of advanced prostate cancer.

Abbott And Alza Will Discuss Ditropan XL Copromotion In Merger Post-Mortem

Abbott and Alza are discussing whether the five-year copromotion agreement for Alza's Ditropan XL (oxybutynin) will survive the Dec. 16 collapse of the pending merger.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts